Emicizumab

George had the opportunity to speak with two UAB Hematology-Oncology fellows who work with the Hemophilia and Bleeding Disorders service at Children’s Hospital of Alabama. They report that the center’s move to hemophilia A therapy using emicizumab (HEMLIBRA) has significantly changed the lives of hemophiliacs in Alabama. One subcutaneous injection per week (or even every other week) has eliminated clinic and home visits and reduced the center’s workload. One of the fellows reports a surprising outcome, several of the center’s patients are actually experiencing depression because they aren’t receiving the attention they required before.